Sildenafil citrate spray and tablets: first results from a single center comparative study
DOI: https://dx.doi.org/10.18565/urology.2022.3.63-70
A.A. Kamalov, D.A. Ohobotov, A.V. Kadrev, R.M. Gorbunov, A.P. Mikhalchenko, A.A. Strigunov, O.Yu. Nesterova, D.A. Tsigura
1) Medical Research and Education Center of Lomonosov Moscow State University, Moscow, Russia;
2) Department of Urology and Andrology of the Faculty of Fundamental Medicine Lomonosov Moscow State University, Moscow, Russia
Objective. Comparison of the effectiveness of liquid and solid forms of sildenafil citrate.
Materials and methods. The study included 16 men with symptoms of erectile dysfunction. Patients were divided into 2 groups depending on the presence of endothelial dysfunction. Each patient received 2 forms of sildenafil citrate with an interval of 3-5 days (spray «Jent» and tablet form). After taking the drug an erotic video was shown (in parallel with penile tumescences monitoring). After 30 and 60 minutes the maximum systolic velocity in the cavernous artery of the penis was determined (Doppler ultrasound).
Results. Sildenafil citrate in liquid form begins to act on average after 10.37 minutes in patients with endothelial dysfunction and 9.00 minutes after taking the drug in patients without it. The effect of the liquid form of sildenafil citrate in patients with endothelial dysfunction developed 1.7 times faster than from taking the tablet form (which was not typical for patients without endothelial dysfunction). 62.5% of patients noted an improvement in the quality of erectile function over the next 24 hours after taking the liquid form of the drug and 25% after taking the tablet form.
Conclusion. Sildenafil citrate in the form of a spray demonstrates a faster onset of effect in patients with endothelial dysfunction, as well as the presence of a residual effect, which is expressed in an improvement in the quality of erectile function within 24 hours after taking the drug. Sildenafil citrate in the form of a spray can be successfully used in clinical practice for the effective treatment of ED symptoms.
About the Autors
Corresponding author: D.A. Ohobotov − Ph.D. (Med.), Urologist, Medical Research and Education Center, Lomonosov Moscow State University, Senior Lecturer, Department of Andrology and Urology, Faculty of Fundamental Medicine, Lomonosov Moscow State University, Moscow, Russia. E-mail: 14072003@rambler.ru
Similar Articles